References
- Blackburn-MunroGDalby-BrownWMirzaNRMikkelsenJDBlackburn-MunroRERetigabine: chemical synthesis to clinical applicationCNS Drug Rev200511112015867950
- BrodieMJLercheHGil-NagelAEfficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsyNeurology201075201817182420944074
- FrenchJAAbou-KhalilBWLeroyRFRandomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsyNeurology201176181555156321451152
- PorterRJPartiotASachdeoRNohriaVAlvesWM205 Study GroupRandomized, multicenter, dose-ranging trial of retigabine for partial-onset seizuresNeurology200768151197120417420403
- TompsonDJCreanCSClinical pharmacokinetics of retigabine/ezogabineCurr Clin Pharmacol20138431933123342983
- BorlakJGasparicALocherMSchupkeHHermannRN– Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type IIMetabolism200655671172116713428
- Lanoxin (digoxin) tablets, USP [package insert]Greenville, NCGlaxoSmithKline2009 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020405s004lbl.pdfAccessed July 16, 2013
- TompsonDJCreanCSReeveRBerryNSEfficacy and tolerability exposure-response relationship of retigabine (ezogabine) immediate-release tablets in patients with partial-onset seizuresClin Ther20133581174118523916044
- US Food and Drug AdministrationDrug Development and Drug Interactions: Regulatory Guidance and Manual for Policies and ProceduresSilver Spring, MDUS FDA2006 Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093606.htmAccessed July 16, 2013
- GiacominiKMHuangSMTweedieDJInternational Transporter ConsortiumMembrane transporters in drug developmentNat Rev Drug Discov20109321523620190787
- BaumanJLDidomenicoRJGalanterWLMechanisms, manifestations, and management of digoxin toxicity in the modern eraAm J Cardiovasc Drugs200662778616555861
- FennerKSTroutmanMDKempshallSDrug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drugClin Pharmacol Ther200985217318118987624
- TuncokYHazanEOtoOGuvenHCatalyurekHKalkanSRelationship between high serum digoxin levels and toxicityInt J Clin Pharmacol Ther19973593663689314088
- SrinivasNRCranberry juice ingestion and clinical drug-drug interaction potentials: review of case studies and perspectivesJ Pharm Pharm Sci201316228930323958198
- PosnerKBrownGKStanleyBThe Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adultsAm J Psychiatry2011168121266127722193671
- FerronGMPaulJFruncilloRMultiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteersJ Clin Pharmacol200242217518211831540
- BrickelNDeRossettSBuraglioMEvansCJonesSInvestigation of the impact of urine handling procedures on interpretation of urinalysis findings and product safety in subjects treated with ezogabineTher Clin Risk Manag2013920721323671389
- European Medicines AgencySummary of Product Characteristics: Trobalt last updated422013LondonEuropean Medicines Agency2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001245/WC500104835.pdfAccessed July 16, 2013